First Case Of COVID-19 Reinfection In The US Confirmed; Exposure to Virus May Not Guarantee Protective Immunity, Says New Lancet Study COVD-19 Science 13/10/2020 • Madeleine Hoecklin Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window) Colorized electron mmicrograph of SARS-CoV-2, the virus that causes COVID-19 (yellow) in a patient sample. A study confirming the first case of a person reinfected with COVID-19 in the US and the fifth such confirmed case of reinfection worldwide was published in The Lancet Infectious Diseases journal on Monday. The findings suggest that protected immunity conferred by infection with SARS-CoV2 – a phenomenon that is not well understood yet – may not result in guaranteed total immunity. Infection with COVID-19 generates neutralizing antibodies in patients, however, the degree of immunity and the susceptibility to reinfection is unknown. In other coronaviruses, loss of immunity can occur within 1-3 years. But the confirmed reports of cases of SARS-CoV-2 reinfection raise questions as to whether this virus will follow the same pattern. The case study of one individual in North America – who was initially infected in April and then reinfected within 48 days in June – provided genomic analyses of SARS-CoV2 on two occasions. The researchers found genetically significant differences between the two variants associated with the two instances of infection. The patient’s second infection was more severe, requiring hospitalization with oxygen support, however, this was not a trend in three of the four other confirmed reinfection cases. The authors provided three hypotheses to explain the severity of the second infection, including the possibility that the patient was infected by a very high dose of virus the second time, inducing a more severe disease; the patient could have come into contact with a virulent version of the virus; and the presence of antibodies could make future infections worse. The findings of this study suggest that infection with SARS-CoV2 may not result in 100 percent protective immunity for all individuals and reinfection can occur within a short time frame. “There are still many unknowns about SARS-CoV-2 infections and the immune system’s response, but our findings signal that a previous SARS-CoV-2 infection may not necessarily protect against future infection,” said Mark Pandori, lead author of the study and director of the Nevada State Public Health Laboratory at the University of Nevada. The study was limited in its scope and calls for more research of reinfection and the degree of immunity for those exposed to COVID-19. While few cases of reinfection have been reported at this point, asymptomatic reinfection is also a possibility and likely is severely underestimated, according to the authors. “Overall, there is a lack of comprehensive genomic sequencing of positive COVID-19 cases both in the USA and worldwide, as well as a lack of screening and testing, which limits the ability of researchers and public health officials to diagnose, monitor, and obtain genetic tracking for the virus,” said Pandori. Research on reinfection and conferred immunity may have significant implications for vaccine development and application. Instances of reinfection likely mean that herd immunity can not be acquired by natural infection, instead, safe and effective vaccines, along with robust vaccination implementation, will be necessary to confer individual and herd immunity. Image Credits: NIAID. Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window) Combat the infodemic in health information and support health policy reporting from the global South. Our growing network of journalists in Africa, Asia, Geneva and New York connect the dots between regional realities and the big global debates, with evidence-based, open access news and analysis. To make a personal or organisational contribution click here on PayPal.